Pepys M B, Hirschfield G M
Centre for Amyloidosis and Acute Phase Proteins, Department of Medicine, Royal Free and University College Medical School, London, UK.
Ital Heart J. 2001 Nov;2(11):804-6.
C-reactive protein (CRP), the classical acute phase reactant, has for some time contributed to both the diagnosis and management of a wide range of infective and inflammatory conditions. More recently with the advent of high sensitivity assays, the hypothesis that atherosclerosis is an inflammatory disease has been strengthened. "Elevated" CRP values predict a poor outcome for patients suffering from unstable coronary syndromes as well myocardial infarction, and large epidemiological surveys have shown that baseline values of CRP can predict future cardiovascular events in those at risk, as well as those otherwise well. Increasingly a direct role for CRP in the pathogenesis of atherosclerosis and post-myocardial infarction inflammation has also been suggested, and CRP itself may prove to be a future therapeutic target in the treatment of atherosclerosis and its consequences.
C反应蛋白(CRP)作为经典的急性期反应物,在一段时间内一直有助于多种感染性和炎症性疾病的诊断与管理。最近,随着高灵敏度检测方法的出现,动脉粥样硬化是一种炎症性疾病的假说得到了强化。“升高的”CRP值预示着不稳定型冠状动脉综合征以及心肌梗死患者的预后不良,并且大型流行病学调查表明,CRP的基线值可以预测有风险人群以及其他健康人群未来发生心血管事件的情况。越来越多的研究表明CRP在动脉粥样硬化发病机制和心肌梗死后炎症中具有直接作用,并且CRP本身可能会成为未来治疗动脉粥样硬化及其后果的治疗靶点。